177944-17-1

Upstream product

• 124-41-4 sodium methylate 
• 79-10-7 acrylic acid 
• 177944-16-0 (R)-N-(but-3-en-1-yl)-N-(α-methylbenzyl)amine 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 67-56-1 methanol 
• 178035-48-8 (1R,5S)-2-((R)-1-phenylethyl)-6-oxa-2-azabicyclo[3.2.1]octan-7-one 

Downstream Products

• 1413286-26-6 C₁₉H₂₅Cl₂NO₅ 
• 321744-26-7 N-Boc-4-hydroxy-2-piperidine carboxylic acid methyl ester 
• 1103929-40-3 methyl 4(R)-(4-nitrobenzoyloxy)-1-[1(R)-phenylethyl]piperidine-2(R)-carboxylate 
• 211058-81-0 methyl (2R,4S)-4-hydroxy-2-piperidinecarboxylate 
• 178035-49-9 (R)-4-Oxo-1-((R)-1-phenyl-ethyl)-piperidine-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Preparation method of griseine key intermediate

The preparation method comprises S1, sequentially adding 4A molecular sieve, acetonitrile and a compound shown in structural formula 1 into acrylic acid, performing a Diels - Alder reaction, and obtaining an intermediate product. TLC A neutralization reag

3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

Validation of high-affinity binding sites for succinic acid through distinguishable binding of gamma-hydroxybutyric acid receptor-specific NCS 382 antipodes

Gamma-hydroxybutyric acid (GHB) binding to multiple sites for the tricarboxylic acid cycle intermediate succinic acid (SUC) has been disclosed recently. In order to better characterize these targets, distinguishable binding of GHB receptor-specific NCS 38

Asymmetric synthesis of cis-(-)-(2R4S)-4-(phosphonomethyl)-2-piperidinecarboxylic acid, a potent NMDA receptor antagonist

The asymmetric synthesis of cis-(-)-(2R4S)-4-(phosphononomethyl)-2-piperidinecarboxylic acid (1), a potent and specific NMDA receptor antagonist, via an olefin-iminium cyclization is described.